“Nabriva closes in on bringing new class of antibiotic to market

“Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could result in a newly approved antibiotic for doctors to utilise – a type of approval that are few and far between.

The trial was able to show that, on a five-day course of treatment, the antibiotic was non-inferior to current treatment, moxifloxacin. It is the second Phase 3 clinical trial that has shown this result, standing the biotech in good stead for taking the antibiotic through to approval.

The major public health benefit of bringing through a new class of antibiotic is the potential to evade antibiotic-resistance bacteria – a problem that is regarded to be a growing threat to global health at present and in the years to come.

In addition, the five-day treatment cycle is also shorter than the seven-day course recommended for the use of moxifloxacin – meaning that there may be interest in using the antibiotic immediately rather than holding it back for future use.

This has meant that analysts have been happy to suggest that the treatment may well go on to reap peak sales of $500 million to $700 million.”

Source: Pharmafile